Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
floxuridine + gemcitabine + cisplatin
- Development stage
- Unknown
- Lead developer
- Roche
- Modality
- Small Molecules
- Administration
- Intravenous, Hepatic Arterial Infusion
01
Overview
A combination chemotherapy regimen consisting of hepatic arterial infusion (HAI) of floxuridine (FUDR) with systemic administration of gemcitabine and cisplatin. This triplet therapy has been studied for the treatment of unresectable intrahepatic or hilar cholangiocarcinoma. The regimen works through multiple mechanisms to disrupt DNA synthesis and cell division in cancer cells.
- Other names
- FUDR + gemcitabine + cisplatingemcitabine/cisplatin plus HAI-FUDR
02
Targets
DNARNR (Ribonucleotide reductase)TS (Thymidylate synthase)
Beyond the preview
Go deeper on floxuridine + gemcitabine + cisplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on floxuridine + gemcitabine + cisplatin.